J. KOVARIK, M.D.; H. GRAF, M.D.; W. WOLOSZCZUK, PH.D.; H.K. STUMMVOLL, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: After anecdotal reports on a decrease of immunoreactive paraphyroid hormone (PTH) levels due to the administration of cimetidine in primary hyperparathyroidism (1,2), therapeutic trials of this agent in patients with secondary hyperparathyroidism have reached conflicting results (3-5). Data on this issue still are too few to draw definite conclusions, and the ratio of beneficial versus no effects of cimetidine on hyperparathyroidism in uremic patients is 12:5, as calculated from the recent literature (3-5). We studied the effect of this H2-receptor blocking agent in a series of patients on chronic intermittent hemodialysis.
Twenty-eight patients on chronic intermittent hemodialysis
KOVARIK J, GRAF H, WOLOSZCZUK W, et al. Cimetidine in Secondary Hyperparathyroidism. Ann Intern Med. 1982;96:379. doi: https://doi.org/10.7326/0003-4819-96-3-379_1
Download citation file:
Published: Ann Intern Med. 1982;96(3):379.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use